The European Union has given regulatory approval to GSK's drug, Blenrep, for treating relapsed or treatment-resistant forms of blood plasma cell cancer.

CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...